For US Healthcare Professionals Only
Publications
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.
*Includes seizure clusters and acute or prolonged seizures
197 result(s)
phase
3
BIMZELX® (bimekizumab-bkzx)
Psoriatic Arthritis
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebocontrolled, active reference BE OPTIMAL study
phase
4/RWE
BRIVIACT® (brivaracetam) CV
Focal Onset Seizures
Effectiveness and tolerability of 12-month brivaracetam in the real world: EXPERIENCE, an international pooled analysis of individual patient records
phase
3
BRIVIACT® (brivaracetam) CV
Focal Onset Seizures
Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open-label, follow-up trial
phase
3
FINTEPLA® (fenfluramine)
Dravet Syndrome
Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial
pre-clinical
ZILBRYSQ® (zilucoplan)
Generalized Myasthenia Gravis
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
phase
3
BIMZELX® (bimekizumab-bkzx)
Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
Correction: Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
phase
4/RWE
CIMZIA® (certolizumab pegol)
Rheumatoid Arthritis
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
phase
3
CIMZIA® (certolizumab pegol)
Rheumatoid Arthritis
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
CIMZIA® (certolizumab pegol)
Rheumatoid Arthritis
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data